Andson’s mission is to accelerate the discovery, development and manufacturing of advanced cell-based therapies. We target the most revolutionary therapies including biologics, cell and gene therapies, tissue engineered medical products and even modern vaccine technologies. While modern therapeutics have shown unprecedented success in reversing the course of genetic disorders and curing cancer, they remain inaccessible due to lengthy developmental timelines, numerous regulatory delays and significant cost overrun during manufacture. We are driven by making therapies widely accessible and affordable to any patient in need.
Mason developed the secretome analysis system (SecrAS) for his PhD dissertation at the Georgia Institute of Technology under Andrei G. Fedorov. During his postdoc, Mason served as the entrepreneurial and technical lead for the project, securing Biolocity and Georgia Research Alliance funding to support the development of the technology. Mason formally cofounded Andson Biotech with Andrei just before it was backed by the well-known accelerator, Ycombinator, for their Winter 2022 batch. Mason has served as a consultant on projects ranging from artificial intelligence cancer diagnosis to resonance-based diagnostics sensors. Before starting his PhD, Mason worked in hands on roles that have benefitted him tremendously as an engineer including a position at a sheet metal/frame shop and as a design engineer for a pharmaceutical packaging company.
Andrei is the Associate Chair for Graduate Studies, Professor and Rae S. and Frank H. Neely Chair at the Georgia Institute of Technology Woodruff School of Mechanical Engineering. His scientific training and expertise are in electrohydrodynamics, complex fluids, (bio)chemical reaction engineering, biophysics and MEMS/nanotechnology. Andrei is also co-founder of a successful start-up company, OpenCell Technologies, which commercializes electrosonic microarray technology for high efficacy biomolecule delivery and gene transfection. As a serial entrepreneur and engineering professor with 20+ years of experience, Andrei has invented numerous technologies in diverse fields from thermal management and power generation devices to bioanalytical technologies. Andrei’s bioanalytical instrumentation development includes microfabricated ion sources for mass spectrometry, scanning electrochemical and mass spectrometry nanoprobes, environmental scanning electron microscopy of biomaterials, and microfluidic devices for separation/pre-concentration of biomolecules and gene/drug delivery. Andrei has authored over 150 archival journal papers and is an inventor on over 50 issued and pending patents. Further information is available at me.gatech.edu/faculty/fedorov.
Edwin M. Horwitz, MD, PhD, is Professor in the Department of Pediatrics at Emory University School of Medicine. A board certified pediatric hematologist/oncologist, Dr. Horwitz serves as Director of Transplantation Biology and Therapeutics at Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta. Dr. Horwitz is a member of the Cancer Immunology research program at Winship Cancer Institute.Dr. Horwitz received his MD and PhD from Indiana University in Bloomington, Indiana where he completed postdoctoral research in Biochemistry. He completed his residency in Pediatrics at Saint Louis Children’s Hospital and his fellowship in Pediatric Hematology/Oncology at Washington University School of Medicine in Saint Louis, Missouri.Dr. Horwitz received his MD and PhD from Indiana University in Bloomington, Indiana where he completed postdoctoral research in Biochemistry. He completed his residency in Pediatrics at Saint Louis Children’s Hospital and his fellowship in Pediatric Hematology/Oncology at Washington University School of Medicine in Saint Louis, Missouri.
Krishanu “Kris” Saha (he/him) is an Associate Professor of Biomedical Engineering and Medical History and Bioethics at the University of Wisconsin-Madison. He was recently named the McPherson Eye Research Institute’s Retina Research Foundation Kathryn and Latimer Murfee Chair for 2019-2022 and an AIMBE Fellow (Class of 2022). His lab is at the Wisconsin Institute for Discovery (WID). He participates on campus in the executive committees of the Stem Cell and Regenerative Medicine Center, Robert F. Holtz Center on Science and Technology Studies, and Forward Bio Institute. Before he arrived in Madison, Dr. Saha studied chemical engineering and biotechnology at Cornell University, the University of Cambridge, and the University of California, Berkeley. In 2007 he became a Society in Science: Branco-Weiss fellow in the laboratory of Professor Rudolf Jaenisch at the Whitehead Institute for Biomedical Research at MIT and in the Science and Technology Studies program at Harvard University with Professor Sheila Jasanoff in Cambridge, Massachusetts. At UW-Madison, major thrusts of his lab involve gene editing and cell engineering of human cells found in the retina, central nervous system, liver, and blood. He has published more than 80 scientific manuscripts, filed several patents, and received awards that include the National Science Foundation CAREER Award, Biomedical Engineering Society’s Rising Star Award, and Gund Harrington Scholar Award. He is the leader of the gene therapy biomanufacturing impact area of the Grainger Institute for Engineering, a member of the National Academies’ Forum on Regenerative Medicine, a co-lead for the T cell testbed within the National Science Foundation’s Center for Cell Manufacturing Technologies (CMaT) and a Co-Chair of the Steering Committee of the National Institutes for Health’s Somatic Cell Genome Editing (SCGE) Consortium.
Bruno Marques, PhD
Bruno Marques has been building and leading the Process & Product Development team at Century Therapeutics toward manufacturing and supply of adult stem cell-derived allogeneic therapies against cancer. Prior to Century, he spent 14 years developing and commercializing biopharmaceutical products at Merck and GlaxoSmithKline. At GSK, Bruno held leadership roles in process development and portfolio management, contributing to the launch of several biological products. He eventually joined GSK’s Cell & Gene Therapy platform as Director of Manufacturing Strategy in support of autologous immunotherapies. Bruno is a Chemical Engineer by training, with a PhD from Carnegie Mellon University and a BS from the Illinois Institute of Technology.
We're currently working with Pharma Co's and Biotechs to accelerate their Mass Spec workflows, and with Advanced Therapies Developers to enable better cell-state characterization.
If we can help accelerate your Mass Spec workflow or help measure critical biomarkers and cell-state for your iPSC and MSC research, please reach out!